MX2015007688A - Composicion de vacunas para uso en poblaciones inmunocomprometidas. - Google Patents

Composicion de vacunas para uso en poblaciones inmunocomprometidas.

Info

Publication number
MX2015007688A
MX2015007688A MX2015007688A MX2015007688A MX2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A MX 2015007688 A MX2015007688 A MX 2015007688A
Authority
MX
Mexico
Prior art keywords
immuno
vaccine composition
vaccine
compromised populations
directed
Prior art date
Application number
MX2015007688A
Other languages
English (en)
Spanish (es)
Inventor
Hans Arwidsson
Anna-Karin Maltais
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of MX2015007688A publication Critical patent/MX2015007688A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015007688A 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas. MX2015007688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077007 WO2014095944A1 (en) 2012-12-17 2013-12-17 Vaccine composition for use in immuno-compromised populations

Publications (1)

Publication Number Publication Date
MX2015007688A true MX2015007688A (es) 2015-09-07

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.
MX2015007753A MX2015007753A (es) 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015007753A MX2015007753A (es) 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos.

Country Status (12)

Country Link
US (2) US20150306204A1 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502997A (enExample)
KR (3) KR20150132092A (enExample)
CN (3) CN104884085A (enExample)
AU (2) AU2013360889C1 (enExample)
BR (2) BR112015014174A2 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1212611A1 (enExample)
MX (2) MX2015007688A (enExample)
RU (2) RU2661408C2 (enExample)
WO (2) WO2014095943A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621524A1 (en) * 2010-09-30 2013-08-07 Eurocine Vaccines AB Improved vaccine compositions
AU2015323334B2 (en) * 2014-09-26 2021-02-25 Seqirus UK Limited Vaccination of immunocompromised subjects
HUE060456T2 (hu) * 2014-09-26 2023-03-28 Seqirus Uk Ltd Immunkompromittált alanyok oltása
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135519B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
PL4135520T3 (pl) * 2020-04-16 2025-02-17 Bayer Aktiengesellschaft Kombinacje związków aktywnych i kompozycje grzybobójcze je zawierające
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
US20250177515A1 (en) * 2022-01-10 2025-06-05 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US20030072764A1 (en) 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
WO2004047862A1 (en) 2002-11-26 2004-06-10 Eurocine Ab Novel amine-based adjuvant
CN103446582A (zh) 2003-08-11 2013-12-18 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
CN101213199B (zh) 2005-06-30 2013-12-18 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
AU2009293595A1 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
EP2621524A1 (en) 2010-09-30 2013-08-07 Eurocine Vaccines AB Improved vaccine compositions

Also Published As

Publication number Publication date
CN104884085A (zh) 2015-09-02
BR112015014243A2 (pt) 2017-07-11
RU2661408C2 (ru) 2018-07-16
BR112015014243A8 (pt) 2019-10-08
JP2016502997A (ja) 2016-02-01
AU2013360890A1 (en) 2015-07-02
KR20210007042A (ko) 2021-01-19
JP2019112448A (ja) 2019-07-11
EP3431101A1 (en) 2019-01-23
AU2013360889B2 (en) 2016-12-01
HK1212611A1 (zh) 2016-06-17
US20150306205A1 (en) 2015-10-29
KR20150132092A (ko) 2015-11-25
RU2661407C2 (ru) 2018-07-16
CN112826929A (zh) 2021-05-25
WO2014095944A1 (en) 2014-06-26
AU2013360889A1 (en) 2015-07-02
WO2014095943A1 (en) 2014-06-26
CA2895023A1 (en) 2014-06-26
RU2015129077A (ru) 2017-01-23
JP2016502996A (ja) 2016-02-01
AU2013360890B2 (en) 2017-04-13
BR112015014174A2 (pt) 2017-07-11
HK1213492A1 (zh) 2016-07-08
EP2931308B1 (en) 2018-10-10
AU2013360889C1 (en) 2017-06-08
EP2931307A1 (en) 2015-10-21
EP2742952A1 (en) 2014-06-18
CN104870010A (zh) 2015-08-26
MX2015007753A (es) 2016-01-08
KR20150132093A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
EP2931308A1 (en) 2015-10-21
RU2015129028A (ru) 2017-01-23
US11065325B2 (en) 2021-07-20
CA2895028A1 (en) 2014-06-26
US20150306204A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
MX2015007688A (es) Composicion de vacunas para uso en poblaciones inmunocomprometidas.
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
EA028928B9 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IN2013MU01749A (enExample)
MY197723A (en) Vaccine compositions for the prevention of dengue virus infection
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
MX2015000446A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
EA201290956A1 (ru) Вакцина против вич
IN2014MN01907A (enExample)
BR112012013199A8 (pt) Composto, composição farmacêutica, e , uso de um composto
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
MX368601B (es) Composicion inmunogenica contra la aeromonas hydrophila.
BR112013023354A2 (pt) vacina para rinite equina
BR112015002984A2 (pt) composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido cítrico.
UA117672C2 (uk) Антибактеріальні сполуки
BR112015003074A2 (pt) composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido etilenodiaminatetra-acético.
BR112013007308A2 (pt) vacina
WO2013109202A3 (en) Pharmaceutical compounds comprising cefetamet